modelImeglimin
Extends from Pharmacolibrary.Drugs.ATC.A.A10BX15.
Information
| name: | Imeglimin | |
| ATC code: | A10BX15 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 280 | L |
| clearance: | 20.2 | L/h |
| other parameters in model implementation | ||
Imeglimin is an oral hypoglycemic agent used for the treatment of type 2 diabetes mellitus. It is a first-in-class tetrahydrotriazine compound that improves glucose-dependent insulin secretion and enhances mitochondrial function. Imeglimin is approved for use in Japan and is under investigation or regulatory review in other regions.
Pharmacokinetics
Pharmacokinetic parameters observed in healthy adult male and female volunteers after oral administration of imeglimin.
References
Chevalier, C, et al., & Fouqueray, P (2021). Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment. Clinical pharmacokinetics 60(4) 485–490. DOI:10.1007/s40262-020-00948-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33169345
Fouqueray, P, et al., & Bolze, S (2022). Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects. Clinical drug investigation 42(9) 721–732. DOI:10.1007/s40261-022-01181-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35867199
Chevalier, C, et al., & Bolze, S (2023). Imeglimin: A Clinical Pharmacology Review. Clinical pharmacokinetics 62(10) 1393–1411. DOI:10.1007/s40262-023-01301-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/37713097
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)